$32 million new equity injection adds to previously announced $59 million New investors Tencent and BGF joined by all existing major shareholders Funds will advance pipeline of novel TCR-CD3 bispecifics in cancer and autoimmune disease 13 November 2025; Cambridge, England – T-Therapeutics, a…
Read More
We look forward to welcoming our staff, visitors and guests over the coming months and years at the One Granta facility. T-Therapeutics Ltd is excited to announce it has taken occupancy of the top floor of One Granta, Granta Park, Cambridge. This space…
Read More
Theodora has over 25 years’ experience in the biotech sector, with a proven track record of dynamic leadership. 10 March 2025; Cambridge, England – T-Therapeutics, a biotechnology company developing next-generation soluble T cell receptor (TCR) therapeutics targeting cancer and autoimmune indications, announces the…
Read More
Fundraise led by Sofinnova Partners, F-Prime Capital, Digitalis Ventures and Cambridge Innovation Capital with participation from Sanofi Ventures and the University of Cambridge Venture Fund Unique transgenic mouse platform harnesses natural power of T cells to build a portfolio of first-in-class cancer medicines…
Read More